CN105132574A

CN105132574A - Marker for diagnosis and treatment of osteoarthritis and application of marker

Info

Publication number: CN105132574A
Application number: CN201510627048.XA
Authority: CN
Inventors: 杨承刚; 任静
Original assignee: Beijing Medintell Bioinformatic Technology Co Ltd
Current assignee: GU'AN BOJIAN BIOTECHNOLOGY CO., LTD.
Priority date: 2015-09-28
Filing date: 2015-09-28
Publication date: 2015-12-09
Anticipated expiration: 2035-09-28
Also published as: CN105132574B

Abstract

The invention discloses a molecular marker-SLC5A8 gene for early diagnosis of osteoarthritis and an expression product of the marker. According to the marker and the expression product thereof, gene chip and protein immune methods prove that an mRNA (Messenger Ribonucleic Acid) expression level and a protein expression level of the SLC5A8 gene in synovial tissues of an osteoarthritis patient are remarkably lower than those of normal synovial tissues. According to the relevance of the SLC5A8 gene and the osteoarthritis gene, the invention discloses a kit for diagnosing the osteoarthritis. The kit can be used for measuring the expression level of the SLC5A8 gene. Because the kit can be used for carrying out diagnosis on the early stage of the osteoarthritis, and thus has a wide application prospect in clinic.

Description

Osteoarthritis diagnosis and treatment mark and application thereof

Technical field

The present invention relates to biological technical field, relate to the purposes of SLC5A8 gene in the diagnosis, treatment of osteoarthritis particularly.

Background technology

Osteoarthritis (Osterarthritis, OA), also referred to as degenerative osteoarthritis, is disease the most general in the elderly and obese person.OA is the disease in joint, but is different from rheumatoid arthritis (RA), and this disease is not systematic, usually only affects one or several joint.This disease causes total destruction of joint cartilage, the sclerosis of below bone, and spur is formed, and causes motor capacity to lose and pain.Final result needs total joint replacement often.

Demography trend shows, to the year two thousand twenty, the crowd affected by joint disease will be increased to 50%, the puzzlement that the whole world will have 5.7 hundred million people to be subject to osteoarthritis.Chinese society progresses into aging society, and therefore we will face the generally popular period of osteoarthritis morbidity.Very important and urgent to the research of this disease.

Former exception of osteoarthritis can occur in joint cartilage, synovial membrane, subchondral bone, ligament or periarticular neural muscular tissue.The infringement of joint cartilage is that osteoarthritis the most significantly changes.Joint cartilage forfeiture is the crucial pathology of osteoarthritis.Along with the decline of proteoglycan content, joint cartilage is slowly degraded gradually.Because the proteoglycan of Human Osteoarthritis, collagen and hyaluronic acid synthesis rate all increase, make the catabolic activity of tissue high especially.It has been generally acknowledged that, protein resolvase and metalloprotease are most important reasons in osteoarthritic joint cartilage is lost.Not having blood vessel and nerve in articular cartilage tissue, is mediated by such as the cytokine etc. of the protein in joint cartilage, synovial tissue or synovial fluid to the reaction of wound, inflammation.Synovial membrane for the normal function maintaining joint, and plays an important role in the generation evolution of osteoarthritis disorders.

Summary of the invention

One is the object of the present invention is to provide to can be used for the molecular marker of osteoarthritis (Osterarthritis, OA) early diagnosis.Compare the diagnostic method of traditional osteoarthritis, what use gene marker to diagnose osteoarthritis has promptness, specificity and susceptibility, thus make patient just can know disease risks in early days in disease, for risk height, take corresponding prevention and therapy measure.

To achieve these goals, the present invention adopts following technical scheme:

The invention provides the application of product in the instrument of preparation diagnosis osteoarthritis detecting SLC5A8 genetic expression.

Further, the product of described detection SLC5A8 genetic expression comprises the product detecting SLC5A8 gene mRNA levels and/or the product detecting SLC5A8 protein level.

Further, the product of described detection SLC5A8 genetic expression comprises: by the expression level of RT-PCR, real-time quantitative PCR, immunodetection, in situ hybridization or chip detection SLC5A8 gene and expression product thereof to diagnose the product of osteoarthritis.

Further, described RT-PCR diagnoses the product of osteoarthritis at least to comprise the primer of a pair specific amplified SLC5A8 gene; The product of described real-time quantitative PCR diagnosis osteoarthritis at least comprises the primer of a pair specific amplified SLC5A8 gene; The product of described immunodetection diagnosis osteoarthritis comprises: the antibody be combined with SLC5A8 protein-specific; The product of described in situ hybridization diagnosis osteoarthritis comprises: with the probe of the nucleic acid array hybridizing of SLC5A8 gene; The product of described chip diagnosis osteoarthritis comprises: protein chip and gene chip; Wherein, protein chip comprises the antibody be combined with SLC5A8 protein-specific, and gene chip comprises the probe with the nucleic acid array hybridizing of SLC5A8 gene.

The primer of a pair specific amplified SLC5A8 gene that described real-time quantitative PCR diagnoses the product of osteoarthritis at least to comprise is as shown in SEQIDNO.5 and SEQIDNO.6.

The product of described detection SLC5A8 genetic expression can be detect SLC5A8 genetic expression reagent, also can be the test kit, chip, test paper etc. that comprise described reagent, also can be the high-flux sequence platform using described reagent.

The instrument of described diagnosis osteoarthritis includes but not limited to chip, test kit, test paper or high-flux sequence platform; High-flux sequence platform is a kind of instrument of special diagnosis osteoarthritis, along with the development of high throughput sequencing technologies, will become work very easily to the structure of the gene expression profile of a people.By contrasting the gene expression profile of Disease and normal population, easily analyze exception and the disease-related of which gene.Therefore, in high-flux sequence, the exception of the SLC5A8 gene purposes that also belong to SLC5A8 gene relevant to osteoarthritis is known, equally within protection scope of the present invention.

Present invention also offers a kind of instrument diagnosing osteoarthritis, described instrument comprises the reagent detecting SLC5A8 genetic expression; Described reagent comprises the antibody of the primer that detects SLC5A8 gene mRNA and/or probe, detection SLC5A8 albumen.

Described instrument includes but not limited to chip, test kit, test paper or high-flux sequence platform.

Wherein, described chip comprises gene chip, protein chip; Described gene chip comprises solid phase carrier and is fixed on the oligonucleotide probe of solid phase carrier, and described oligonucleotide probe comprises the oligonucleotide probe for SLC5A8 gene for detecting SLC5A8 gene transcription level; Described protein chip comprises solid phase carrier and is fixed on the specific antibody of SLC5A8 albumen of solid phase carrier; Described gene chip can be used for detecting the expression level of the multiple genes (such as, relevant to osteoarthritis multiple genes) comprising SLC5A8 gene.Described protein chip can be used for detecting the expression level of the multiple protein (such as relevant to osteoarthritis multiple protein) comprising SLC5A8 albumen.By being detected by multiple mark with osteoarthritis simultaneously, the accuracy rate of osteoarthritis diagnosis greatly can be improved.

Wherein, described test kit comprises gene detecting kit and protein immunization detection kit; Described gene detecting kit comprises the reagent for detecting SLC5A8 gene transcription level; Described protein immunization detection kit comprises the specific antibody of SLC5A8 albumen.Further, described reagent comprises the reagent used needed in RT-PCR, real-time quantitative PCR, immunodetection, in situ hybridization or chip method detection SLC5A8 gene expression dose process.Preference, described reagent comprises primer for SLC5A8 gene and/or probe.The primer and probe that may be used for detecting SLC5A8 gene expression dose is easily designed according to the nucleotide sequence information of SLC5A8 gene.

Described test paper comprises the reagent detecting SLC5A8 genetic expression.

Described high-flux sequence platform comprises the reagent detecting SLC5A8 genetic expression.

Can be DNA, RNA, DNA-RNA mosaic, PNA or other derivative with the probe of the nucleic acid array hybridizing of SLC5A8 gene.The length of described probe does not limit, if complete specific hybrid, with object nucleotide sequence specific binding, any length can.The length of described probe can be as short as 25,20,15,13 or 10 bases longs.Equally, the length of described probe can grow to 60,80,100,150,300 base pairs or longer, even whole gene.Because different probe length has different impacts to hybridization efficiency, signal specificity, the length of described probe is at least 14 base pairs usually, the longlyest generally be no more than 30 base pairs, best with 15-25 base pair with the length of object nucleotide sequence complementary.Described probe self-complementary sequences most preferably less than 4 base pairs, in order to avoid affect hybridization efficiency.

Further, the specific antibody of described SLC5A8 albumen comprises monoclonal antibody, polyclonal antibody.The specific antibody of described SLC5A8 albumen comprise complete antibody molecule, any fragment of antibody or modification (such as, chimeric antibody, scFv, Fab, F (ab ') 2, Fv etc.As long as described fragment can retain the binding ability with SLC5A8 albumen.Well known to a person skilled in the art during preparation for the antibody of protein level, and the present invention can use any method to prepare described antibody.

In specific embodiment of the invention scheme, the primer of described detection SLC5A8 gene mRNA comprises the primer pair shown in SEQIDNO.5 and SEQIDNO.6.

Present invention also offers the application of promotor in the medicine of preparation treatment osteoarthritis of SLC5A8 gene and/or its expression product.

Described promotor comprises the reagent promoting SLC5A8 genetic expression and the reagent promoting SLC5A8 gene expression product; The reagent of described promotion SLC5A8 genetic expression comprises the reagent of the reagent promoting genetic transcription, the reagent promoting gene translation, promotion SLC5A8 protein content; The reagent of described promotion SLC5A8 gene expression product comprises the reagent of the reagent promoting SLC5A8 gene expression product stability, the reagent promoting SLC5A8 gene expression product activity, promotion SLC5A8 gene expression product function.

Particularly, the reagent of described promotion SLC5A8 genetic expression comprises: the reagent that the reagent containing SLC5A8 gene, the carrier carrying SLC5A8 gene or host cell are formed, the reagent containing SLC5A8 protein.

Promotor of the present invention may be used for disappearance or the deficiency of supplementary endogenic SLC5A8 albumen on the one hand, by improving the expression of SLC5A8 albumen, thus the osteoarthritis that treatment causes because of SLC5A8 hypoproteinosis.May be used for the activity or the function that promote SLC5A8 albumen on the other hand, thus treatment osteoarthritis.

The carrier carrying gene of the present invention is various carrier known in the art, as commercially available carrier, comprises plasmid, clay, phage, virus etc.

In the present invention, term " host cell " comprises prokaryotic cell prokaryocyte and eukaryotic cell.The example of conventional prokaryotic host cell comprises intestinal bacteria, Bacillus subtilus etc.Conventional eukaryotic host cell comprises yeast cell, insect cell and mammalian cell.Preferably, this host cell is eukaryotic cell, as Chinese hamster ovary celI, COS cell etc.

Present invention also offers a kind of pharmaceutical composition being used for the treatment of osteoarthritis, described pharmaceutical composition comprises the promotor of SLC5A8 gene recited above and/or its expression product.

Further, medicine of the present invention also comprises pharmaceutically acceptable carrier, carrier, and this kind of carrier comprises (but being not limited to): thinner, vehicle are if water etc., weighting agent are as starch, sucrose etc.; Tackiness agent is as derivatived cellulose, alginate, gelatin and polyvinylpyrrolidone; Wetting agent is as glycerine; Disintegrating agent is as agar, calcium carbonate and sodium bicarbonate; Absorption enhancer quaternary ammonium compound; Tensio-active agent is as cetyl alcohol; Absorption carrier is as kaolin and soap clay; Lubricant is as talcum powder, calcium stearate and magnesium, polyoxyethylene glycol etc.

The mode of drugs delivery tissue of the present invention or cell can be divided into the mode in external or body.Vitro formats comprises by the medicine containing SLC5A8 gene or containing in the drugs delivery cell of SLC5A8 protein, then by Transplanted cells or feed back in body.In body, mode comprises directly by the medicine containing SLC5A8 gene or containing in the infusion of medicine in-vivo tissue of SLC5A8 protein.

Medicine of the present invention also can with the drug combination of other treatment osteoarthritis, multi-medicament conbined usage can mention the success ratio for the treatment of greatly.

In the context of the present invention, " SLC5A8 gene " comprises the polynucleotide of any function equivalent of SLC5A8 gene and SLC5A8 gene.SLC5A8 gene comprises and has more than 70% homology with SLC5A8 gene (NC_000012.12) DNA sequence dna in current international common core sequence databank GeneBank, and coding identical function protein DNA sequence;

Preferably, the encoding sequence of SLC5A8 gene comprises any DNA molecular following:

(1) DNA sequence dna shown in SEQ ID NO.1;

(2) under strict conditions with 1) DNA sequence dna that limits hybridizes and identical function protein DNA sequence of encoding;

(3) DNA sequence dna limited with (1) or (2) has 70%, preferably, more than 90% homology, and coding identical function protein DNA molecule.

In specific embodiment of the invention scheme, the encoding sequence of described SLC5A8 gene is the DNA sequence dna shown in SEQIDNO.1.

In the context of the present invention, SLC5A8 gene expression product comprises the partial peptide of SLC5A8 albumen and SLC5A8 albumen.The partial peptide of described SLC5A8 albumen contains the functional domain relevant to osteoarthritis.

" SLC5A8 albumen " comprises any function equivalent of SLC5A8 albumen and SLC5A8 albumen.Described function equivalent comprises SLC5A8 albumen conservative variation's protein or its active fragments, or its reactive derivative, allelic variant, natural mutation, induced mutants, can with the protein coded by the DNA of the DNA hybridization of SLC5A8 under high or low stringent condition.

Preferably, SLC5A8 albumen is the protein with following amino acid sequences:

(1) protein be made up of the aminoacid sequence shown in SEQ ID NO.2;

(2) aminoacid sequence shown in SEQIDNO.2 had the protein derivative by the aminoacid sequence shown in SEQIDNO.2 of identical function with the aminoacid sequence shown in SEQIDNO.2 through the replacement of one or several amino-acid residue and/or disappearance and/or interpolation.The amino acid whose number replacing, lack or add is generally 1-50, preferably 1-30, and more preferably 1-20,1-10 is individual best.

(3) with the aminoacid sequence shown in SEQIDNO.2, there is at least 80% homology (being also called sequence iden), more preferably, with the aminoacid sequence shown in SEQIDNO.2 at least about 90% to 95% homology, be often 96%, 97%, 98%, 99% homology aminoacid sequence form polypeptide.

In specific embodiment of the invention scheme, described SLC5A8 albumen is the protein with the aminoacid sequence shown in SEQIDNO.2.

Usually, it is known that in a protein one or more amino acid whose modification can not affect the function of protein.Those skilled in the art can approve the amino acid that changes single amino acids or little per-cent or be conservative modifications to indivedual interpolations of aminoacid sequence, disappearance, insertion, replacement, and wherein the change of protein produces the protein with identity function.Intimate amino acid whose Conservative substitution tables is provided to be well known in the art.

By adding the fusion rotein that the example of the protein of an amino acid or multiple Modification of amino acid residues is SLC5A8 albumen.Peptide or protein with SLC5A8 protein fusion are not limited, as long as the fusion rotein of gained retains the biologic activity of SLC5A8 albumen.

SLC5A8 albumen of the present invention also comprises the non-conservative modification to the aminoacid sequence shown in SEQIDNO.2, as long as the protein through modifying still can retain the biologic activity of SLC5A8 albumen.The amino acid number suddenlyd change in this type of modifying protein normally 10 or less, such as 6 or less, such as 3 or less.

In the context of the present invention, " diagnosis osteoarthritis " had both comprised and had judged whether experimenter has suffered from osteoarthritis, also comprised and judge whether experimenter exists the risk suffering from osteoarthritis.

In the context of the present invention, " treatment osteoarthritis " divides from the change of state of disease, can comprise the healing completely of the alleviation of disease, disease.

Advantage of the present invention and beneficial effect:

Late Cambrian of the present invention SLC5A8 genetic expression is relevant to osteoarthritis, by detecting the expression of SLC5A8 in experimenter synovial tissue, can judge whether experimenter suffers from osteoarthritis or judge whether experimenter exists the risk suffering from osteoarthritis, thus instruct clinicist to provide prevention scheme or treatment plan to experimenter.

Present invention finds a kind of new molecular marked compound-SLC5A8 gene, compare traditional detection means, gene diagnosis more in time, more special, sensitiveer, the early diagnosis of osteoarthritis can be realized, thus reduce the mortality ratio of osteoarthritis.

Accompanying drawing explanation

Fig. 1 display utilizes the expression of genechip detection SLC5A8 gene in synovial tissue;

Fig. 2 display utilizes Westernblot to detect the expression of SLC5A8 albumen in synovial cell;

Fig. 3 display utilizes QPCR on transcriptional level, detect the process LAN situation of SLC5A8 gene;

Fig. 4 display utilizes Westernblo to detect the process LAN situation of SLC5A8 albumen.

Concrete embodiment

Below in conjunction with drawings and Examples, the present invention is further detailed explanation.Following examples are only not used in for illustration of the present invention and limit the scope of the invention.The experimental technique of unreceipted actual conditions in embodiment, usual conveniently condition, the people such as such as Sambrook, molecular cloning: laboratory manual (NewYork:ColdSpringHarborLaboratoryPress, 1989) condition described in, or according to the condition that manufacturer advises.

The differential expression of SLC5A8 gene in embodiment 1OA synovial tissue and normal synovial tissue

The synovial tissue of 60 routine OA patients comes from patient OA of the capable knee prosthesis of BJ Union Hospital's orthopaedics or villusectomy.Case used meets the Case definition about OA that Altam proposes.40 routine normal synovial tissue come from BJ Union Hospital's orthopaedics, are trauma surgery patient synovial tissue of joint.Get supernatant after OA patient's synovial fluid (SF) high speed centrifugation ,-80 DEG C of storages are stand-by.Clinical sample used in this research, all carries out knowing the inside story to patient and informs and pass through through Ethics Committee of the court.

1, the extraction of RNA is organized

1) in the clear area that less RNase disturbs, use the mortar containing appropriate liquid nitrogen to take in vitro synovial tissue sample and be about 20mg, be ground to pestle Powdered;

2) sample is transferred in a centrifuge tube not containing the 2mL of RNA enzyme;

3) add 300uLLysissolution, be placed in homogenizer, fully grind 1-5min;

4) 12000g, 4 DEG C, centrifugal 10min, transfer supernatant is in the centrifuge tube of new 1.5mL;

5) add 600ulRNase-FreeWater, mix with whirlpool device;

6) 20ul Proteinase K is added, at 55 DEG C of temperature bath 15min, continuous vortex mixing;

7) 14000g, room temperature, centrifugal 1min, makes pellet cell debris bottom centrifuge tube, gets supernatant and transfers to another one not containing in the centrifuge tube of RNA enzyme 1.5mL;

8) add 95% ethanol of 450ul, vortex mixes;

RNA adsorbs:

9) getting 650ul is added in centrifugal column containing the lysate of ethanol, the centrifugal 1min of 14000g;

10) abandon lower floor, reset collection tube on post;

11) according to the capacity of lysate, 9 are repeated) ~ 10) step;

12) 400ulWashsolution is added, the centrifugal 2min of 14000g;

13) abandon lower floor, post is placed on a new collection tube;

DNase process:

14) 100ulEnzymeIncubationBuffer and 15ulDNaseI is added, the centrifugal 1min of 14000g;

15) solution in collection tube is moved in post again;

16) room temperature places 15min;

RNA washs:

17) add 400ulWashsolution, the centrifugal 1min of 14000g, abandons lower floor, resets collection tube on post;

18) add 400ulWashsolution, the centrifugal 2min of 14000g, abandons collection tube;

RNA wash-out:

19) pillar is put into 1.7mLElution pipe;

20) 30ulElutionBuffer is added;

21) the centrifugal 2min of 200g, makes solution fully be combined with post, then the centrifugal 1min of 14000g.

2, the mass analysis (NanoDrop1000 spectrophotometer) of RNA sample

It is 1.8-2.2 that NanoDrop1000 spectrophotometer detects RNA sample: OD260/OD280.

3, gene chip hybridization and scanning

After the linearized amplification of total serum IgE, cy3-UTP marks, and the cRNAs after fluorescent mark adopts RNEASYMiniKit purifying, carries out fragmentation process with the RNAFragmentationReagents of Amhion to the cRNAs marked.Adopt people's full genome chip of expression spectrum (4x44K gene) of Agilent company of the U.S., in chip hybridization stove, 65 DEG C of hybridization 17h, then wash-out, dyeing, finally use AgilentDNAMicroarrayScanner scanner scanning.

4, chip data treatment and analyses

Chip after hybridization after chip scanner reading of data point, by data importing analysis software, the natural logarithm absolute value for two groups of ratios be greater than 2.0 or be less than 0.5 gene as difference expression gene.

5, statistical procedures

Adopt SPSS13.0 statistical software to carry out data analysis, group difference compares employing one-way analysis of variance method, and P<0.05 difference has significant.

6, result

Result display (as shown in Figure 1), compared with normal people, in Human Osteoarthritis synovial tissue, the mRNA level in-site of SLC5A8 gene significantly reduces, and difference has statistical significance (P<0.05).

The differential expression of SLC5A8 albumen in embodiment 2OA synovial tissue and normal synovial tissue

1, step

1.1 synovial tissue's cell injuring model

By the synovial tissue of aseptic acquisition with after PBS cleaning, the tissue block into about 1mmx1mmx1mm is repeatedly sheared with aseptic operation scissors, after adding collagenase II (0.5mg/ml) 37 DEG C, digestion 2h, filter through 200 order gauzes, centrifugal remove supernatant after, cell is resuspended in DMEM nutrient solution, is placed in 37 DEG C, 5%CO ₂cultivate in cell culture incubator.After cell grows up to fusiformis and be in blocks, carry out Secondary Culture.After cell reached for the 3rd generation, add respectively FITC mark mouse anti human CD3, CD14, CD19 and PE mark mouse anti human CD11b mark, flow cytomery identify.It is that fibroblast-like synoviocyte (Fibroblast-likeSynoviocytes, FLS) is for this research that above-mentioned 4 kinds of marks are negative cell.

The extraction of 1.2 total protein of cell

Phase of taking the logarithm, well-grown fiber-like synovial cell carried out the extraction of total protein of cell, carried out the operation of protein extraction according to the specification sheets of the full cell extraction test kit of EpiQuik.

1.3Westernblot detect

The protein quantification of extraction is carried out SDS-PAGE electrophoresis, carries out transferring film afterwards, close, primary antibodie hatches, two anti-ly to hatch, develop the color.

2, statistical procedures

Use ImageJ software to analyze the gray-scale value of protein band, with β-actin for internal reference, the gray-scale value of SLC5A8 protein band is normalized.Result data is all represent in the mode of mean+SD, adopts SPSS13.0 statistical software to carry out statistical study, and difference between the two adopts t inspection, thinks to have statistical significance as P<0.05.

3, result

As shown in Figure 2, compared with normal people, in Osteoarthritic Synovium tissue, the expression level of SLC5A8 albumen significantly reduces result, and difference has statistical significance (P<0.05).

Embodiment 3SLC5A8 gene expression plasmid builds

1, the structure of SLC5A8 expression vector

According to encoding sequence (as shown in the SEQIDNO.1) design of amplification primers of SLC5A8 gene, primer sequence is as follows: forward primer is 5 '-GGCATCGGCACCTTCGTG-3 ' (SEQIDNO.3), and reverse primer is 5 '-AAACGAGTCCCATTGCTCTT-3 ' (SEQIDNO.4).From cDNA library (the clontech company becoming Human fetal spleen, article No.: the encoding sequence of the SLC5A8 gene of amplification total length 638831), above-mentioned cDNA sequence is inserted in the eukaryotic expression vector pcDNA3.1 of restriction enzyme BamHI and XhoI double digestion after restriction enzyme BamHI and XhoI double digestion, connects the recombinant vectors pcDNA3.1-SLC5A8 obtained and is used for subsequent experimental.

2, transfection

OA fibroblast-like synoviocyte is divided into two groups, is respectively control group (transfection pcDNA3.1 empty carrier) and SLC5A8 process LAN group (transfection pcDNA3.1-SLC5A8).Use liposome 2000 to carry out the transfection of carrier, the instruction to specifications of concrete transfection method is carried out.The working concentration of pcDNA3.1 empty carrier and pcDNA3.1-SLC5A8 is 0.5 μ g/ml.

3, QPCR detects

Ordinary method is utilized to operate 3.1 extract cell total rna.

3.2 reverse transcription

With RT Buffer, reverse transcription synthesis cDNA is carried out to l μ g total serum IgE.Adopt 25 μ l reaction systems, each sample gets 1 μ g total serum IgE as template ribonucleic acid, adds following component respectively: DEPC water in PCR pipe, 5 × RT Buffer, 10mmol/LdNTP, 0.1mmol/lDTT, 30 μm of mol/lOligodT, 200U/ μ lM-MLV, template ribonucleic acid.Hatch 1h for 42 DEG C, 72 DEG C of 10min, of short duration centrifugal.

3.3QPCR

Adopt 25 μ l reaction systems, each sample arranges 3 parallel pipes, and all amplified reactions are above to ensure the reliability of result all in triplicate.Prepare following reaction system: SYBRGreen polymerase chain reaction system 12.5 μ l, forward primer (5 μMs) 1 μ l, reverse primer (5 μMs) 1 μ l, template cDNA2.0 μ l, without enzyme water 8.5 μ l; The forward primer sequence of amplification SLC5A8 gene is 5 '-CAGCACCTACAATGAGACA-3 ' (SEQIDNO.5), and reverse primer sequences is 5 '-AAGAATACCAGTTATCCATCAGT-3 ' (SEQIDNO.6); The forward primer sequence of amplification GAPDH gene is 5 '-TTTAACTCTGGTAAAGTGGATAT-3 ' (SEQIDNO.7), reverse primer sequences is 5 '-GGTGGAATCATATTGGAACA-3 ' (SEQIDNO.8), and operations is all in carrying out on ice.Amplification program is: 95 DEG C of 5min, (95 DEG C of 10s, 60 DEG C of 60s) * 45 circulation.Using SYBRGreen as fluorescent marker, in the enterprising performing PCR reaction of LightCycler fluorescence real-time quantitative PCR instrument, by melt curve analysis analysis and electrophoresis determination object band, Δ Δ CT method carries out relative quantification.

3.4 statistical method

Experiment has all come for 3 times according to repetition, result data is all represent in the mode of mean+SD, adopt SPSS13.0 statistical software to carry out statistical study, the difference between two groups adopts t inspection, thinks to have statistical significance as P<0.05.

4, Western detects

Concrete steps are with embodiment 2.

2, result

As shown in Figure 3, compared with the cell of transfection pcDNA3.1 empty carrier, in the cell of transfection pcDNA3.1-SLC5A8, the mRNA level in-site of SLC5A8 significantly raises, and difference has statistical significance (P<0.05); As shown in Figure 4, compared with the cell of transfection pcDNA3.1 empty carrier, in the cell of transfection pcDNA3.1-SLC5A8, the protein level of SLC5A8 significantly raises, and difference has statistical significance (P<0.05).

OA fibroblast-like synoviocyte proliferation experiment under embodiment 4 incentive condition

1, OA fibroblast-like synoviocyte proliferation experiment under incentive condition

1.1 step

OA fibroblast-like synoviocyte is inoculated in 96 porocyte culture plates, every hole 2x10 ³cells/ hole/200 μ l, 37 DEG C, 5%CO ₂after incubator hatches 24 hours, add (1:5 dilution) in synovial fluid, continue to hatch 24 hours, in the culture hole of required detection, every hole adds 10 μ lCK-8 solution respectively afterwards, continue to hatch 1h in cell culture incubator, measure each hole, 450nm place absorbance (OD value).

1.2 statistical method

Experiment has all come for 3 times according to repetition, result data is all represent in the mode of mean+SD, adopt SPSS13.0 statistical software to carry out statistical study, difference between the two adopts t inspection, thinks to have statistical significance as P<0.05.

1.3 result

Result is as shown in table 1, and does not add compared with control group that synovial fluid stimulates, and the FLS propagation that adding synovial fluid stimulates obviously is accelerated, and difference has statistical significance (P<0.05).

Table 1FLS cell OD value

Experimental group	OD value (optical density(OD))
		Do not add synovial fluid	0.1597±0.003
Add synovial fluid	0.2716±0.005

Embodiment 5SLC5A8 gene overexpression is on the impact of OA fibroblast-like synoviocyte propagation under incentive condition

1, step

With 2 × 10 ⁵/ ml density is inoculated in 96 porocyte culture plates, after cell attachment, carries out cell transfecting according to the method for embodiment 3, and each experimental group design three wells, every hole 100 μ l, is positioned over 37 DEG C, 5%CO ₂hatch in incubator, after transfection 24h, add synovial fluid (1:5 dilution), continue to hatch 24 hours, in the culture hole of required detection, every hole adds 10 μ lCK-8 solution respectively afterwards, continue to hatch 1h in cell culture incubator, measure each hole, 450nm place absorbance (OD value).

2, statistical method

Experiment has all come for 3 times according to repetition, result data is all represent in the mode of mean+SD, employing SPSS13.0 statistical software carries out statistical study, difference between SLC5A8 gene overexpression group and control group adopts t to check, and thinks to have statistical significance as P<0.05.

3, result

As shown in Table 2, compared with the cell of transfection pcDNA3.1 empty carrier, the cell proliferation under transfection pcDNA3.1-SLC5A8 inhibits synovial fluid to stimulate, difference has statistical significance (P<0.05) to result.

Table 2FLS cell OD value

Experimental group	OD value (optical density(OD))
		pcDNA3.1	0.2692±0.004
pcDNA3.1-SLC5A8	0.1738±0.002

[0146] the impact that embodiment 6SLC5A8 gene overexpression is bred OA fibroblast-like synoviocyte

1, step

With 2 × 10 ⁵/ ml density is inoculated in 96 porocyte culture plates, after cell attachment, carries out cell transfecting according to the method for embodiment 3, and each experimental group design three wells, every hole 100 μ l, is positioned over 37 DEG C, 5%CO ₂hatch in incubator, after transfection 48h, in the culture hole of required detection, every hole adds 10 μ lCK-8 solution respectively, continues to hatch 1h in cell culture incubator, measures each hole, 450nm place absorbance (OD value).

2, statistical method

3, result

Result as shown in Table 3, compared with the cell of transfection pcDNA3.1 empty carrier, obviously slow down, and difference has statistical significance (P<0.05) by transfection pcDNA3.1-SLC5A8 cell proliferation.

Table 3FLS cell OD value

Experimental group	OD value (optical density(OD))
		pcDNA3.1	0.1614±0.002
pcDNA3.1-SLC5A8	0.1045±0.003

The explanation of above-described embodiment is just for understanding method of the present invention and core concept thereof.It should be pointed out that for the person of ordinary skill of the art, under the premise without departing from the principles of the invention, can also carry out some improvement and modification to the present invention, these improve and modify and also will fall in the protection domain of the claims in the present invention.

Claims

1. detect the application of product in the instrument of preparation diagnosis osteoarthritis of SLC5A8 genetic expression.

2. application according to claim 1, is characterized in that, described product comprises: by RT-PCR, real-time quantitative PCR, immunodetection, in situ hybridization chip or high-flux sequence detection of platform SLC5A8 genetic expression to diagnose the product of osteoarthritis.

3. application according to claim 2, is characterized in that, described RT-PCR diagnoses the product of osteoarthritis at least to comprise the primer of a pair specific amplified SLC5A8 gene; The product of described real-time quantitative PCR diagnosis osteoarthritis at least comprises the primer of a pair specific amplified SLC5A8 gene; The product of described immunodetection diagnosis osteoarthritis comprises: the antibody be combined with SLC5A8 protein-specific; The product of described in situ hybridization diagnosis osteoarthritis comprises: with the probe of the nucleic acid array hybridizing of SLC5A8 gene; The product of described chip diagnosis osteoarthritis comprises: protein chip and gene chip; Wherein, protein chip comprises the antibody be combined with SLC5A8 protein-specific, and gene chip comprises the probe with the nucleic acid array hybridizing of SLC5A8 gene.

4. application according to claim 3, is characterized in that, the primer of a pair specific amplified SLC5A8 gene that described real-time quantitative PCR diagnoses the product of osteoarthritis at least to comprise is as shown in SEQIDNO.5 and SEQIDNO.6.

5. diagnose an instrument for osteoarthritis, it is characterized in that, described instrument comprises the reagent detecting SLC5A8 genetic expression; Described reagent comprises the antibody of the primer that detects SLC5A8 gene mRNA and/or probe, detection SLC5A8 albumen.

6. instrument according to claim 5, is characterized in that, the primer of described detection SLC5A8 gene mRNA comprises the primer pair shown in SEQIDNO.5 and SEQIDNO.6.

The application of promotor in the medicine of preparation treatment osteoarthritis of 7.SLC5A8 gene and/or its expression product.

8. application according to claim 7, it is characterized in that, the reagent of the reagent of described promotion SLC5A8 genetic expression, the reagent promoting SLC5A8 gene expression product stability, promotion SLC5A8 gene expression product activity, the reagent of promotion SLC5A8 gene expression product function.

9. application according to claim 8, is characterized in that, the reagent promoting the reagent of SLC5A8 genetic expression to comprise the reagent containing SLC5A8 gene, the carrier carrying SLC5A8 gene or host cell to be formed, the reagent containing SLC5A8 protein.

10. be used for the treatment of a pharmaceutical composition for osteoarthritis, it is characterized in that, described pharmaceutical composition comprises the promotor according to any one of 7-9.